LOINC Code 44678-1: Margin(s) involved by invasive carcinoma Nom (Prostate tumor)
44678-1 is a LOINC code used to identify Margin(s) involved by invasive carcinoma Nom (Prostate tumor) in laboratory and clinical observation data. You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges. LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Margin(s) involved by invasive carcinoma. It is commonly used with the system or sample type Prostate tumor.
What is this code?
LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Margin(s) involved by invasive carcinoma. It is commonly used with the system or sample type Prostate tumor.
When is it used?
- Used in lab systems, EHRs, and clinical data exchange.
- May identify a test, observation, survey item, or clinical document request rather than a diagnosis.
- Status: ACTIVE
- Order vs observation: Observation
What it does not mean
- The code identifies the observation or test, not the actual result.
Key facts
- Margin(s) involved by invasive carcinoma in Prostate tumor
- Margin(s) involved by invasive carcinoma
- Cancer; Finding; Findings; Margin(s) involved by IC; Nominal; PATH.HISTO; PATHOLOGY; Point in time; Prost; Prostatic; PrT; Random; S prime; tumors; tumour; tumours
Where you may see this code
You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges.
Common synonyms
Frequently asked questions
About this content
This page is prepared by HealthAssure's clinical team using official coding standards from LOINC. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.